

## Company Overview

Medexus Pharmaceuticals Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading prescription products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

## Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 2020

Nov 16 2020, 5:15 PM EST

## Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients

Nov 16 2020, 8:00 AM EST

## Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call

Nov 9 2020, 8:30 AM EST

## Investor Relations

Crescendo Communications, LLC  
David Waldman / Natalya Rudman  
T: 212-671-1020  
[mdp@crescendo-ir.com](mailto:mdp@crescendo-ir.com)

## Management Team

### Ken d'Entremont

Chief Executive Officer and Director

### Roland Boivin

Chief Financial Officer

### Michael Adelman

General Manager, U.S. Operations

### Michael Pine

Senior Vice President of Business Development and Strategy

### Richard Labelle

Vice President Allergy, Pediatric and OTC Portfolios, Canadian Operations

## Medexus Pharmaceuticals, Inc.

1 Place du Commerce  
Suite 225  
Verdun, QC H3E 1A2  
Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.